PCCA/ANNA by IFA with Reflex to Titer and Immunoblot
Also known as: PCCA/ANNA
Use
This test aids in the diagnosis of paraneoplastic neurologic syndromes (PNDS) associated with malignancy. It serves to distinguish between PNDS and other inflammatory disorders of the nervous system by detecting Purkinje cell cytoplasmic and neuronal nuclear antibodies. These antibodies can be associated with various cancers such as small-cell lung cancer, neuroblastoma, fallopian tube and breast cancer, ovarian cancer, and Hodgkin's lymphoma. The presence of one or more of these antibodies supports the diagnosis of PNDS and suggests an underlying neoplasm.
Special Instructions
Not provided.
Limitations
This test has been developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. The test is performed in a CLIA certified laboratory and is intended for clinical purposes. It is important to note that negative results do not rule out the presence of a PNDS or associated malignancy. Variability in antibody expression over time and differences in antibody detection systems may affect test outcomes.
New York Approved
Methodology
Immunoassay (IHC)
Biomarkers
Purkinje Cell Cytoplasmic Antibody IgG
Protein
LOINC Codes
- 61177-2 - Paraneoplastic Ab Ser Ql IF
Result Turnaround Time
1-6 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
0.75 mL
Container
Serum separator tube (SST)
Collection Instructions
Separate serum from cells ASAP or within 2 hours of collection. Transfer serum to an ARUP standard transport tube.
Storage Instructions
Refrigerated
Causes for Rejection
Contaminated, heat-inactivated, hemolyzed, or lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 month |
Other tests from different labs that may be relevant